Efficacy and Safety of Lenvatinib as a Conversion Therapy for HCC
NCT04241523
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
50
Enrollment
OTHER
Sponsor class
Conditions
Hepatocellular Carcinoma (HCC)
Interventions
DRUG:
Lenvatinib 4 mg Oral
Sponsor
Shanghai Zhongshan Hospital
Collaborators
[object Object]
[object Object]
[object Object]